Good news and bad news in biotech IPO market

07/23/2013 | Xconomy

The market for biotech initial public offerings has rebounded this year, spurred by generalist investors who previously shunned the industry, but the party won't last long, Luke Timmerman writes. Neglected diseases will get a boost, as will regional innovation hubs, and small companies will gain negotiating leverage, but some investors will lose interest after they lose money, Timmerman writes.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ